The randomized trial of Peginterferon alfa 2a or alfa2b with simeprevir and ribavirin for chronic hepatitis C
Not Applicable
Recruiting
- Conditions
- Chronic hepatitis C
- Registration Number
- JPRN-UMIN000013597
- Lead Sponsor
- Graduate School of Medical Sciences, Kumamoto University, Department of Gastroenterology and Hepatology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 140
Inclusion Criteria
Not provided
Exclusion Criteria
1.pregnancy or breast feeding female severe allergy to IFN 2, 3.severe allergy to RBV or nucreosid analogue 4.uncontrolled cardiac diseases 5.Hemoglobinopathies 6.chronic renal failure or less than 50 ml /min of CCr 7.severe psychiatric disorder 8.severe cirrhotic patients 9.The history of interstitial pneumonitis 10.Autoimmune hepatitis 11.The history of the allergy to biochemical agents 12.receiving disallowed drugs 13.uncontrolled diabetes mellitus 14.patients with HCC(except for curative patients) 15.co-infection of HBV and/or HIV 16.patients who not permit the participate this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The rate of sustained virological response 24 weeks after the end of treatment
- Secondary Outcome Measures
Name Time Method